2018
Inhibition of Type 1 Phosphodiesterse Confers Therapeutic Benefit to Proteinopathy‐based HFpEF in Mice
Zhang H, Rekhter M, Wang X. Inhibition of Type 1 Phosphodiesterse Confers Therapeutic Benefit to Proteinopathy‐based HFpEF in Mice. The FASEB Journal 2018, 32: 903.14-903.14. DOI: 10.1096/fasebj.2018.32.1_supplement.903.14.Peer-Reviewed Original ResearchCardiac ubiquitin-proteasome systemProtein kinase GHeart failureEjection fractionTg micePDE1 inhibitionTherapeutic strategiesUbiquitin-proteasome systemLeft ventricular end-diastolic volumeVentricular end-diastolic volumeKaplan-Meier survival analysisInhibition groupNon-Tg miceLV posterior wallProtein kinase AEnd-diastolic volumeHeart failure casesTreatment of HFPotential therapeutic strategyNew therapeutic strategiesMonths of ageFull-text articlesInsufficiency contributesMortality benefitPharmacological therapy
2015
Priming the proteasome by protein kinase G: a novel cardioprotective mechanism of sildenafil
Zhang H, Wang X. Priming the proteasome by protein kinase G: a novel cardioprotective mechanism of sildenafil. Future Cardiology 2015, 11: 177-189. PMID: 25760877, PMCID: PMC4370174, DOI: 10.2217/fca.15.3.Peer-Reviewed Original ResearchConceptsProtein kinase GProtein quality controlMost cellular proteinsKinase GNovel cardioprotective mechanismProteasome enhancementCardiac protein quality controlProtein kinase G activationMisfolded proteinsProtein hemostasisCellular proteinsProteasomal degradationCardiac proteinopathyHuman failing heartsProteinProteasomeNew therapeutic strategiesG activationTherapeutic strategiesMajor pathogenic factorFunctional insufficiencyCardioprotective mechanismsLarge subsetDegradationMechanism